BlackRock Investment Management’s Sage Therapeutics SAGE Stock Holding History

BlackRock Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$6.66M	Buy	130,472 +138	+0.1%	+$6.5K	0.01%	1388
2016 Q3	$6M	Buy	130,334 +20,250	+18%	+$824K	0.01%	1351
2016 Q2	$3.32M	Buy	110,084 +48,332	+78%	+$1.61M	﹤0.01%	1729
2016 Q1	$1.98M	Buy	61,752 +8,128	+15%	+$286K	﹤0.01%	2018
2015 Q4	$3.13M	Sell	53,624 -47	-0.1%	-$2.33K	﹤0.01%	1747
2015 Q3	$2.27M	Sell	53,671 -3,960	-7%	-$244K	﹤0.01%	1982
2015 Q2	$4.21M	Buy	57,631 +38,521	+202%	+$2.48M	0.01%	1633
2015 Q1	$960K	Buy	19,110 +447	+2%	+$19.2K	﹤0.01%	2546
2014 Q4	$683K	Buy	18,663 +1,203	+7%	+$44.8K	﹤0.01%	2815
2014 Q3	$550K	Buy	+17,460	New	+$506K	﹤0.01%	2912

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock Investment Management's SAGE Position: Q4 2016 in Review

BlackRock Investment Management increased its Sage Therapeutics (SAGE) stake by 0.11% in Q4 2016, buying an estimated $6.5K and bringing the position to 130,472 shares worth $6.66M. The position accounts for 0.01% of the portfolio, ranked #1388.

BlackRock Investment Management first reported a position in SAGE in Q3 2014 and has held it in 10 quarters since. 165 funds tracked by Wall St. Rank hold SAGE as of Q4 2016.

BlackRock Investment Management held 130,472 shares of Sage Therapeutics worth $6.66M as of Q4 2016.
BlackRock Investment Management bought 138 Sage Therapeutics shares in Q4 2016, an estimated $6.5K.
Sage Therapeutics made up 0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #1388 holding.
BlackRock Investment Management first reported a position in Sage Therapeutics in Q3 2014 and has held it in 10 quarters since.
165 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.